Page 712 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

670 PRINCIPES ACTIFS INTERFERANTAVEC LA TUBULINE (POISONS DUFUSEAU

WILLIAMS H. J. et al., NMR and molecular modeling study of the conformations of taxol
and of its side chain methylester in aqueous and non-aqueous solution, Tetrahedron,
1993, 49, 6545-6560.
HEPPERLE H. et GEORG G. 1., Taxol analogs (review), Drugs Fut., 1994, 19, 573-584.
HOLTON R. A. et al., First total synthesis of taxol. 1. Functionalization of the B ring,J. Am.
Chem. Soc.1994, 116, 1597-1598.
HOLTON R. A. et al., First total synthesis of taxol. 2. Completion of the C and D rings,
J. Am. Chem. Soc., 1994, 116, 1599-1600.
NICOLAOU K. C. et al., Total synthesis of taxol, Nature, 1994, 367, 630-633.
FABRE J. L. et al., Docetaxel (review), Drugs Fut., 1995, 20, 464-471.
FARINA V., The chemistry and pharmacology of Taxof1J and its derivatives, Pharmaco-
chemistry Library, 1995 Vol. 22, Timmerman H., ed., Elsevier Science B. V., Amster-
dam, 1.
MASTROPAOLO O. et al., Crystal and molecular structure of paclitaxel (Taxol), Proc.
Nat/. Acad. Sei., États-Unis, 1995, 92, 6920-6924.
VYAS O. M. et KADOW J. F., Paclitaxel : a unique tubulin interacting anticancer agent.
Progress in Medicinal Chemistry, 1995, 32, 289-337.
BLAGOSKLONNY M. V. et al., Taxol-induced apoptosis and phosphorylation of Bcl-2
protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway,
Cancer Research, 1996, 56, 1851-1854.
GUÉRITTE-VOEGELEIN F. et al., Influence de la conformation des taxoïdes sur la réac-
tivité chimique et l'activité, Actualités de Chimie Thérapeutique, 1997, 173-187.
KEARNS C., Pharmacokinetics of taxanes, Pharmacotherapy suppl., 1997, 17, 105S-
109S.
LOEB C. et al., [3H] (Azidophenyl)ureido Taxoid Photolabels Peptide Amino Acids 281-
304 of a-Tubulin, Biochemistry, 1997, 36, 3820-3825.
SACKETT D. et FOJO T., Taxanes, Cancer Chemotherapy and Biological Response
ModifiersAnnual 17, 1997, 59-79.
EISENHAUER E. A. et al., The taxoids. Comparative clinical pharmacology and therapeu-
tic potential (review), Drugs, 1998, 55, 5-30.
OJIMA 1. et al., New weapons in the fight against cancer, Chemtech, 1998, 31-36.
VISENT-DUMORTIER et al., Les Taxanes : aspects pharmaceutiques, Lyon Pharm.,
1998, 49, 328-335.
WATSON J. M. et al., Identification of the structural region of taxol that may be respon-
sible for cytokine gene induction and cytotoxicity ln human ovarian cancer cells, Can-
cer Chemother Pharmac0l, 1998, 41, 391- 397.
HARRIS C. R. et DANISHEFSKY S. J., Complex target-oriented synthesis in the drug
discovery process : a case history in the dEpoB series, J. Org. Chem., 1999, 64, 8434-
8456.
MERRILL C. et al., Apoptotic cell death induced by baccatin Ill, a precursor of paclitaxel,
may occur without G,/M arrest, Cancer Chemother Pharmacol, 1999, 44, 444-452.
OJIMA 1. et al., Recents advances in the medicinal chemistry of taxoids with novel 13-
amino acid side chains, Curr. Med. Chem., 1999, 6, 927-954.
RODI D. J. et al., Screening of a library of phage-displayed peptides identifies human
Bcl-2 as a Taxol-binding protein, J. Mol. Bi0l., 1999, 285, 197-203.